Altimmune (ALT) Invested Capital (2012 - 2026)

Altimmune (ALT) posted quarterly Invested Capital of $35.0 million for Q1 2026, little changed quarter-over-quarter from $35.0 million in Q4 2025.

Analysis

Altimmune (ALT) Invested Capital (2012 - 2026) Analysis & Trends

Altimmune (ALT) has reported Invested Capital for 8 consecutive years, with $35.0 million the latest figure, recorded in Q1 2026.

In Q1 2026, Invested Capital changed N/A year-over-year to $35.0 million; the TTM figure through Mar 2026 stood at $100.0 million (changed N/A YoY), while the FY2025 annual figure was $35.0 million, changed N/A from the prior year.
Invested Capital was little changed at $35.0 million in Q1 2026 per ALT's latest filing, from $35.0 million in the prior quarter.
Across five years, Invested Capital topped out at $35.0 million in Q4 2025 and bottomed at $4.3 million in Q1 2022.
Historically, Invested Capital has averaged $20.9 million across 3 years, with a median of $15.0 million in 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Invested Cap. (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	33.70 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	7.35 Bn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	6.25 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	-
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	19.13 Bn
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	1.30 Bn
10	Altimmune	636.07 Mn	636.07 Mn	-	508.95 Mn

Historic Data

Download Data